Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.41 |
| ▸ | AKT1S1 | Q96B36 | 7/20 | 0.34 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11986935 | 0.89 | NNMT (0.37) | NISCH | |
| SCHEMBL17041865 | 0.78 | UHRF1 (0.55) | UHRF1AKT1S1NOS3NOS1NOS2 | |
| SCHEMBL782837 | 0.75 | PDE3B (0.38) | — | |
| SCHEMBL23089693 | 0.73 | UHRF1 (0.41) | UHRF1AKT1S1NOS3NOS1NOS2 | |
| SCHEMBL22387691 | 0.73 | NOS3 (0.36) | NOS3NOS1NOS2 | |
| SCHEMBL580764 | 0.73 | UHRF1 (0.41) | UHRF1AKT1S1NOS3NOS1NOS2 | |
| SCHEMBL23085984 | 0.73 | UHRF1 (0.41) | UHRF1AKT1S1NOS3NOS1NOS2 | |
| SCHEMBL22019768 | 0.73 | GRM4 (0.36) | NOS3NOS1NOS2 | |
| SCHEMBL16196456 | 0.73 | UHRF1 (0.41) | UHRF1AKT1S1NOS3NOS1NOS2 | |
| SCHEMBL1330038 | 0.73 | UHRF1 (0.41) | UHRF1AKT1S1NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-20210317122-A1 | SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11 | Cantero Therapeutics, Inc. | 2021-10-14 | — | — | US | disclosed |
| US-20210017182-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-01-21 | — | — | US | disclosed |
| US-10280171-B2 | Heterocyclic inhibitors of PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-05-07 | — | — | US | disclosed |
| US-20170342078-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-11-30 | — | — | US | disclosed |
| US-20170342078-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-11-30 | — | — | US | disclosed |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8680114-B2 | AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
| US-8088794-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7858623-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858623-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2010-07-01 | — | — | US | disclosed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342078-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | UHRF1 1262/4885AKT1S1 1077/4885NISCH 4486/4885 |
| US-20230339900-A1 | CASEIN KINASE 1 DELTA MODULATORS | CSNK1D, CSNK1A1, CSNK2A1 | UHRF1 2963/4885AKT1S1 891/4885NISCH 4715/4885 |
| US-20210017182-A1 | HETEROCYCLIC INHIBITORS OF PTPN11 | PTPRJ, PTPN11, PTPRCAP | UHRF1 1262/4885AKT1S1 1077/4885NISCH 4486/4885 |
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | UHRF1 2637/4885AKT1S1 5/4885NISCH 3613/4885 |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | HGF, HGFAC, MET | UHRF1 4010/4885AKT1S1 1058/4885NISCH 955/4885 |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | UHRF1 2637/4885AKT1S1 5/4885NISCH 3613/4885 |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | HGF, HGFAC, MET | UHRF1 3639/4885AKT1S1 1508/4885NISCH 976/4885 |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | UHRF1 2637/4885AKT1S1 5/4885NISCH 3613/4885 |
| US-10280171-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | UHRF1 1262/4885AKT1S1 1077/4885NISCH 4486/4885 |
| US-20210317122-A1 | SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11 | PTPN11, PTPRJ, PTPRCAP | UHRF1 1539/4885AKT1S1 997/4885NISCH 3810/4885 |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | UHRF1 4010/4885AKT1S1 1058/4885NISCH 955/4885 |
| US-11840536-B2 | Heterocyclic inhibitors of PTPN11 | PTPRJ, PTPN11, PTPRCAP | UHRF1 1262/4885AKT1S1 1077/4885NISCH 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.